Effect of simvastatin on the expression of farnesoid X receptor in diabetic animal models of altered glucose homeostasis

Chinese Medical Journal

Volumn 127, Issue 2, 2014, Pages 218-224

  Wang, Lu Lu ^a   Huang, Xian Ping ^a   Hu, Su ^a   Ma, Xiao Li ^a   Wang, Shao Lian ^a   Pang, Shu Guang ^a  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Farnesoid X receptor; Glucose metabolism; Liver X receptor; Simvastatin; Sterol regulatory element binding protein 1c

Indexed keywords

CHOLESTEROL; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GLUCOSE BLOOD LEVEL; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUID INTAKE; FOOD INTAKE; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN RESISTANCE; MALE; ORPHAN NUCLEAR RECEPTORS; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84892621458     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131591     Document Type: Article

References (30)

1. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
2. Kearney P, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
3. Lalli CA, Pauli JR, Prada PO, Cintra DE, Ropelle ER, Velloso LA, et al. Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet. Metabolism 2008; 57: 57-65.
4. Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem 2012; 287: 1861-1873.
5. Prawitt J, Staels B. Bile acid sequestrants: glucose-lowering mechanisms. Metab Syndr Relat Disord 2010; 8: 3-8.
6. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53: 890-898.
7. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006; 281: 11039-11049.
8. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-1109.
9. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007; 56: 239-247.
10. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 1006-1011.
11. Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 2009; 296: 543-552.
12. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418.
13. Fiorucci S, Mencarelli A, Distrutti E, Zampella A. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003; 278: 2563-2570.
14. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein AI transcription via a negative FXR response element. J Clin Invest 2002; 109: 961-971.
15. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005; 146: 984-991.
16. Côté I, Sock ETN, Lévy É, Lavoie J-M. An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training. Eur J Nutr 2012; 52: 1-10.
17. Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52: 1455-1464.
18. Shao S, Yang Y, Yuan G, Zhang M, Yu X. Signaling molecules involved in lipid-induced pancreatic beta-cell dysfunction. DNA Cell Biol 2013; 32: 41-49.
19. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011; 305: 2556-2564.
20. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191.
21. Li T, Chiang JY. Nuclear receptors in bile acid metabolism. Drug Metab Rev 2013; 45: 145-155.
22. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005; 146: 984-991.
23. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, et al. FXR deficiency causes reduced atherosclerosis in Ldlr-/-mice. Arterioscler Thromb Vasc Biol 2006; 26: 2316-2321.
24. Hebanowska A. Mechanisms of bile acid biosynthesis regulation-autoregulation by bile acids. Postepy Biochem 2011; 57: 314-323.
25. Park WH, Pak YK. Insulin-dependent suppressesion of cholesterol 7α hydroxylase is a possible link between glucose and cholesterol. Exp Mol Med 2011; 43: 571-579.
26. Habeos I, Ziros PG, Psyrogiannis A, Vagenakis AG, Papavassiliou AG. Statins and transcriptional regulation: the FXR connection. Biochem Biophys Res Commun 2005; 334: 601-605.
27. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-1109.
28. Baptissart M, Vega A, Martinot E, Baron S, Lobaccaro JM, Volle DH. Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling? Cell Mol Life Sci 2013; 70: 4511-4526.
29. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006; 281: 11039-11049.
30. Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta 2010; 1802: 363-372.